Transgene

Transgene Profit per Employee

The Profit per Employee of Transgene (TNG.PA) as of Nov 18, 2026 is -213,654.09 EUR. In the previous year, Profit per Employee was -140,427.67 EUR — a change of 52.15% (lower).

Profit per Employee

-213,654.09EUR

YoY

52.15%

Last updated:

Profit per Employee of Transgene is 2024 -213,654.09 EUR. Profit per Employee of Transgene was 2023 -140,427.67 EUR. It decreases by 52.15% lower compared to the previous year.

The Transgene Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2017
-202,981.13 EUR
Jan 1, 2018
50,477.99 EUR
Jan 1, 2019
-118,264.15 EUR
Jan 1, 2020
-108,371.07 EUR
Jan 1, 2021
-122,867.92 EUR
Jan 1, 2022
-206,314.47 EUR
Jan 1, 2023
-140,427.67 EUR
Jan 1, 2024
-213,654.09 EUR
The Transgene Profit per Employee history
YEARProfit per EmployeeYoY
-213,654.09EUR+52.15%
-140,427.67EUR-31.94%
-206,314.47EUR+67.92%
-122,867.92EUR+13.38%
-108,371.07EUR-8.37%
-118,264.15EUR-334.29%
50,477.99EUR-124.87%
-202,981.13EUR+28.04%
-158,534.59EUR-45.64%
-291,660.38EUR-4.49%
-305,383.65EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Profit per Employee of Transgene is -213,654.09 EUR in 2024.

Profit per Employee of Transgene changed from -140,427.67 EUR to -213,654.09 EUR, representing a 52.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Transgene since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Transgene

All Key Metrics — Transgene